Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy  by Bradbury, Andrew W. et al.
Bypass versus Angioplasty in Severe Ischaemia of
the Leg (BASIL) trial: An intention-to-treat
analysis of amputation-free and overall survival in
patients randomized to a bypass surgery-first or a
balloon angioplasty-first revascularization strategy
Andrew W. Bradbury, BSc, MD, MBA, FRCSEd,a,b Donald J. Adam, MD, FRCSEd,a Jocelyn Bell, PhD,b
John F. Forbes, PhD,c F. Gerry R. Fowkes, PhD, FRCPE,d Ian Gillespie, MD, FRCR,e
Charles Vaughan Ruckley, ChM, FRCSEd, CBE,f and Gillian M. Raab, PhD,g on behalf of the BASIL trial
Participants,* Birmingham and Edinburgh, United Kingdom
Background: A 2005 interim analysis of the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial showed
that in patients with severe lower limb ischemia (SLI; rest pain, ulceration, gangrene) due to infrainguinal disease, bypass
surgery (BSX)-first and balloon angioplasty (BAP)-first revascularization strategies led to similar short-term clinical outcomes,
although BSX was about one-third more expensive and morbidity was higher. We have monitored patients for a further 2.5
years and now report a final intention-to-treat (ITT) analysis of amputation-free survival (AFS) and overall survival (OS).
Methods: Of 452 enrolled patients in 27 United Kingdom hospitals, 228 were randomized to a BSX-first and 224 to a
BAP-first revascularization strategy. All patients were monitored for 3 years and more than half for >5 years.
Results: At the end of follow-up, 250 patients were dead (56%), 168 (38%) were alive without amputation, and 30 (7%)
were alive with amputation. Four were lost to follow-up. AFS and OS did not differ between randomized treatments
during the follow-up. For those patients surviving 2 years from randomization, however, BSX-first revascularization was
associated with a reduced hazard ratio (HR) for subsequent AFS of 0.85 (95% confidence interval [CI], 0.5-1.07; P 
.108) and for subsequent OS of 0.61 (95% CI, 0.50-0.75; P  .009) in an adjusted, time-dependent Cox proportional
hazards model. For those patients who survived for 2 years after randomization, initial randomization to a BSX-first
revascularization strategy was associated with an increase in subsequent restricted mean overall survival of 7.3 months
(95% CI, 1.2-13.4 months, P  .02) and an increase in restricted mean AFS of 5.9 months (95% CI, 0.2-12.0 months,
P  .06) during the subsequent mean follow-up of 3.1 years (range, 1-5.7 years).
Conclusions: Overall, there was no significant difference in AFS or OS between the two strategies. However, for those
patients who survived for at least 2 years after randomization, a BSX-first revascularization strategy was associated with
a significant increase in subsequent OS and a trend towards improved AFS. (J Vasc Surg 2010;51:5S-17S.)Severe leg ischemia (SLI), characterized by rest/night
pain and tissue loss (ulceration, gangrene), leads to signif-
icant morbidity and mortality as well as to the consumption
of considerable health and social care resources in devel-
oped and developing countries.1 Many observational data
examining outcomes after surgical and endovascular inter-
ventions have been published from many different coun-
tries around the world2-28 and many opinions expressed
about the relative merits of these two approaches to revas-
cularization.29-32 Despite this, the absence of level I evi-
dence from randomized trials (RCTs) means that there is
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are best treated.33,34
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guinal disease.35
The term severe leg ischemia (SLI), rather than critical
limb ischemia (CLI), was intentionally used when the trial
was designed in the late 1990s because trial organizers
wished specifically to admit patients with chronic, poten-
tially limb threatening, ischemia but who did not necessar-
ily have ankle pressures 50 mm Hg and thus did not
strictly fulfill the requirements of the term CLI as defined
by the European Consensus Document.36 It is also impor-
tant to emphasize at the outset that BASIL was not a trial of
all patients presenting with SLI due to infrainguinal disease.
Rather, BASIL only considers those who required and were
fit for immediate or early revascularization and in whom
there was uncertainty (gray area of clinical equipoise) about
which treatment strategy (BSX first or BAP first) was pref-
erable in the judgement of the responsible surgical and
interventional teams. Lastly, it is important to bear in mind
that the BASIL trial compares two strategies, not just
procedures, and the outcomes reported here therefore take
into account events occurring both before and after the
index procedure.37
An interim intention-to-treat (ITT) analysis reported
in 2005 indicated that short-term amputation free survival
(AFS) and overall survival (OS) were similar after the two
strategies, but BSX was more morbid during the first 12
months and approximately one-third more expensive.35
However, there was a suggestion that after 2 years from
randomization, patients would be more likely to remain
alive and without amputation if they had been originally
randomized to BSX. Although this result was statistically
significant, it was based on a post hoc analysis performed
after the survival curves had been viewed, and the number
of end points after 2 years was relatively small. To deter-
mine whether this apparent advantage of BSX was main-
tained in the longer term, patients have now been moni-
tored for a further 2.5 years. We now report a final ITT
analysis of AFS and OS in patients randomized to a BSX-
first or a BAP-first revascularization strategy for SLI due to
infra-inguinal disease.
METHODS
All patients who participated in BASIL provided writ-
ten informed consent. The study was approved by the
Multi-centre Research Ethics Committee (MREC) for Scot-
land. The BASIL trial is registered with theNational Research
Register (NRR) and as an International StandardRandomised
Controlled Trial, number ISRCTN 45398889 (http://www.
controlled-trials.com/ISRCTN45398889/45398889 17-
05-2009).
Design. The BASIL trial methods have been pub-
lished in detail elsewhere.35 Briefly, between August 1999
and June 2004, consultant vascular surgeons and interven-
tional radiologists in 27 UK hospitals randomized 452
patients with SLI to a BSX-first or a BAP-first treatment
strategy whose diagnostic imaging showed a pattern of
disease which, in their joint opinion, could equally well be
treated by infrainguinal BSX or BAP. SLI was defined asischemic rest and/or night pain (requiring opiate analgesia)
and/or tissue loss (ulcer and/or gangrene) of presumed
arterial etiology (regardless of ankle pressure) present for
2 weeks. It is important to emphasize that a patient could
only be randomized if there was genuine doubt on the part
of the responsible vascular team about which strategy was in
the patient’s best interests, and if the patient required,
agreed to, and was fit for urgent or immediate revascular-
ization by either means.
After patients were randomized by center, patients in
each center were then further stratified into four groups by
clinical presentation (rest pain only vs tissue loss) and ankle
pressure (50 vs 50 mm Hg). Preintervention angio-
grams were scored according to the Bollinger method.38,39
Centers were encouraged to undertake the assigned
procedure as soon as possible after patient randomization.
Responsible consultant vascular surgeons and intervention-
alists were permitted to use their normal custom and prac-
tice with regard to preintervention assessment, the inter-
vention itself, and postintervention follow-up.
Data on all first and repeat interventions were prospec-
tively collected, as were data on clinical outcomes. For the
first year of follow-up, four dedicated research nurses trav-
elled regularly to trial centers to collect data on randomized
patients. Thereafter, the local vascular teams collected the
data. The trial coordinator liaised continually with these
teams and travelled at least annually to trial centers to
collect data from paper-based and electronic hospital infor-
mation systems regarding further procedures and primary
outcomes. Where necessary, primary care doctors and
nurses were also contacted.
In addition, end point data for deaths, amputations,
and further procedures were collected through national
audit mechanisms. Specifically, details of patients recruited
in Scottish centers were logged with the Information and
Statistics Division (ISD) of the National Health Service in
Scotland. The status of all patients alive at the end of
follow-up was confirmed by linkage to the General Registry
Office (Scotland) or the Office of National Statistics (ONS)
England death records. Hospital admissions for Scottish
patients were obtained by record linkage to Scottish Mor-
bidity Records (SMR-01).
Final follow-up data were gathered from visits to all
centers in the 6 months before the end of follow-up. These
data were checked and updated to the final follow-up date
using data from UK National Health Service (NHS)
sources, including the ISD of the NHS in Scotland using
record linkage to SMR-01 records, General Registry Office
(Scotland), and the ONS England death records, hospital
records, and general practitioners.
In keeping with the 2005 interim analysis,35 the main
clinical end points reported here are AFS, defined as patient
alive without amputation of trial leg at transtibial level or
above, and OS, defined as death from any cause. Secondary
outcomes included postprocedural morbidity, reinterven-
tions, health-related quality of life (HRQOL), and the use
of hospital resources. Analyses of these secondary clinical
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analysis are the subject of further separate reports.37,40
Statistical analysis. The power to detect a hazard
ratio (HR) of 0.5 for BSX vs BAP from new events (ampu-
tation, death) after 2 years from randomization was esti-
mated at 90% with P .05. This was based on a simulation
study using a Weibull parametric survival model using
separate hazards before and after 2 years from randomiza-
tion. Because the expected direction of difference was
known, a one-sided test was specified and agreed by the
funding body (HTA) and datamonitoring committee. This
present, second statistical analysis was conducted according
to a prespecified protocol that was finalized before further
follow-up data from 2005 to 2008 were available. In keep-
ing with accepted reporting standards for RCTs, all analyses
presented here are by ITT. A by-treatment-received analy-
sis of AFS and OS is the subject of a separate report.37
A Cox proportional hazards model was used to exam-
ine AFS and OS with a time-dependent HR to compare
treatments taking different values before and after 2 years
from randomization. For the survival analyses, patients with
no report of death were censored at the date of last clinical
contact or at the date of the last record linkage to NHS data
(end February 2007 for ISD and end July 2007 for ONS).
Four patients who were lost to follow-up and who were
thought unlikely to have their deaths recorded in the UK
were censored at their last follow-up times; these were all
within 1 year and 1 month of randomization.
RESULTS
The baseline characteristics of the 228 patients ran-
domized to BSX and the 224 randomized to BAP were
similar and have been previously reported in detail, as have
the details of the BSX and BAP procedures performed.35 As
is typical of patients presenting with SLI, many were el-
derly, 40% were diabetic, 33% were still smoking, most
had a significant cardiovascular medical history, and the SLI
in 25% affected both legs. Disease severity in the trial leg
was rest pain only and an ankle pressure50mmHg in 93;
rest pain only and an ankle pressure 50 mm Hg in 23;
tissue loss and an ankle pressure 50 mm Hg in 222, and
tissue loss and an ankle pressure50mmHg in 114. Thus,
74% of patients had tissue loss (ulceration, gangrene) and
30% had ankle pressures 50 mm Hg, thus fulfilling the
European Consensus pressure criteria for CLI.36
Apart from four patients lost to follow-up, there was a
minimum of 3 years complete follow-up for all patients, with
54% beingmonitored for5 years; the longest follow-up was
just 7 years. The status of the patients at the end of
follow-up is reported in Table I. Procedures undertaken
out to 3 years are shown in the Consolidated Standards of
Reporting Trials (CONSORT) diagram (Fig 1).
For follow-up period as a whole, restricted mean sur-
vival41 did not differ significantly between randomized
groups for AFS, with 3.84 years for BSX and 3.62 years for
BAP (difference, 0.22 years; 95% confidence interval [95%
CI], 0.34 to 0.78) or OS, with 4.48 years for BSX and
4.25 years for BAP (difference, 0.23 years; 95% CI, 0.33to 0.79). However, as had been anticipated from the in-
terim analysis,35 the time-dependent Cox proportional
hazards analysis prespecified in the statistical plan showed
the relative HRs for amputation and death after BSX and
BAP were more favorable for BSX at later times. Specifi-
cally, whereas hazards were slightly (nonsignificantly)
higher for BSX out to 2 years from randomization, OS was
significantly better after 2 years in those patients initially
randomized to BSX (Table II). Although there was also a
trend towards better AFS in the BSX group after 2 years,
this was not statistically significant. These findings are
shown in the survival curves in Figs 2 and 3.
For those patients who survived to 2 years after ran-
domization, initial randomization to BSX was associated
with a significant increase in subsequent restrictedmeanOS
of 7.3 months (P  .02) and a nonsignificant increase in
restricted mean AFS of 5.9 months (P  .06) during a
subsequent mean follow-up of 3.1 years (range, 1-5.7
years) compared with randomization to BAP.
To explore further information coming from new data
collected since the interim census date (February 2005), we
also performed a person-years analysis of events that oc-
curred after 2 years from randomization. This showed that
the trend to improved AFS after 2 years seen after random-
ization to BSX in the earlier preliminary (2005) analysis was
not continued. This was because relatively more amputa-
tions occurred after 2 years in those who had been assigned
to BSX. By contrast, the trend to significantly fewer deaths
in those randomized to BSX did continue. These data are in
agreement with and support the results of the prespecified
Cox proportional hazards analysis.
There was no evidence for differential effectiveness by
any of the interactions prespecified in the statistical proto-
col; namely, Bollinger angiography scores, Trans-Atlantic
Inter-Society Consensus (TASC) II classification, stratifica-
tion group at randomization, and a predictive score based
on a combination of all baseline covariates. This lack of
differential effectiveness was present for the follow-up pe-
riod as a whole and when the periods before and after 2
years from randomization were analyzed separately. No
other interactions, outside of those prespecified, were ex-
amined.
DISCUSSION
Background to the current analysis. The UK Na-
Table I. Patient status at final follow-up
Variable
All
(n  452)
No. (%)
Angioplasty
(n  224)
No. (%)
Bypass
(n  228)
No. (%)
Lost to follow-up 4 1 3
In follow-up or dead 448 (100) 223 (100) 225 (100)
Status
Dead 250 (56) 131 (59) 119 (53)
Alive with amputation 30 (7) 10 (4) 20 (9)
Alive no amputation 168 (38) 82 (37) 86 (38)tional Institute of Health Research (NIHR) Health Tech-
e, smo
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ac.uk/) invited tenders for a trial to compare surgical and
endovascular approaches to the treatment of lower limb-
threatening ischemia in 1996, and our group was chosen to
run the trial. The perceived need for such a trial was borne
out of growing concerns regarding the lack of RCT evi-
dence in the field and the trend towards angioplasty—and
away from surgery—in the absence of any supporting con-
trolled data.
It is striking that 10 years later, the BASIL trial
remains the only RCT to have addressed this question.
Most, if not all, of the other studies that have been pub-
Fig 1. Consolidated Standards of Reporting Trials (CO
out to 3 years.
Table II. Cox proportional hazards analysis, by time from
End point
Time from
randomization Estim
Amputation free survival
Unadjusted 2 years 1.0
2 years 0.8
Adjustedb 2 years 1.0
2 years 0.8
Overall survival
Unadjusted 2 years 1.1
2 years 0.6
Adjustedb 2 years 1.1
2 years 0.6
CI, Confidence interval; HR, hazard ratio.
aTest of homogeneity of HR before and after 2 years from randomization.
bAdjusted for stratification, serum creatinine, body mass index, diabetes, aglished since then have exhibited one or more of the meth-odologic limitations that originally prompted the commis-
sioning of the BASIL trial in the late 1990s. Specifically,
these other studies were often retrospective,42-44 from a sin-
gle-center,42,45,46 were single-surgeon, small,47,48 hadmixed
patientswith claudication and SLI,46,47,49 hadmixedaortoiliac
and infrainguinal disease,45 provided only short15,47,49 and/or
incomplete44 follow-up, excluded technical failures,50 and used
nonclinical surrogate end points.51
Despite these methodologic problems, the paucity of
good quality data, and concerns over durability,52 espe-
cially in patients with more advanced disease,53 certain
review articles continue to strongly advocate an endo-
RT) diagram shows patient journeys and interventions
omization 2 years and 2 years
HR surgery vs angioplasty Treatment by
time period
P valuea95% CI P value
(0.78-1.41) 0.76 .26
(0.55-1.16) 0.24
(0.76-1.39) 0.85 .23
(0.50-1.07) 0.11
(0.83-1.65) 0.36 .013
(0.43-0.90) 0.01
(0.84-1.68) 0.32 .011
(0.50-0.75) 0.009
king, statin at baseline, and below knee Bollinger score.NSOrand
ate
5
0
3
5
7
2
9
1vascular rather than a surgical approach to SLI as the
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ischemia.54,55
The BASIL trial aimed to determine whether a BSX-
Fig 2. Curves show amputation-free survival in trial patients ran-
domized to a bypass surgery-first or ballon angioplasty-first revas-
cularization strategy.
Fig 3. Curves show overall survival in trial patients randomized to
a bypass surgery-first or a balloon angioplasty-first revasculariza-
tion strategy.first or a BAP-first revascularization strategy in patientswith SLI due to infrainguinal arterial disease was associated
with a better outcome in terms of AFS,OS,HRQL, and use
of hospital resources.40 A preliminary analysis of the BASIL
trial reported in 2005 indicated that short-term clinical
outcomes from the two strategies were similar but that
surgery was more morbid and was approximately one-third
more expensive during the first 12 months.35
There was, however, a suggestion that after 2 years
from intervention, patients would be more likely to remain
alive and without major limb amputation if they had been
originally randomized to surgery. Although this difference
was statistically significant, the finding was based on a post
hoc analysis of a relatively small number of late events. The
statistical advice was to exercise caution and to consider this
an interim finding in need of further testing.
To confirm or refute this apparent long-term advantage
for surgery, further funding was obtained from the HTA to
allow trial patients to be monitored for a further 2.5 years.
This additional follow-up period was chosen on the basis of a
careful statistical power calculation based on observed and
anticipated events rates. The final ITT analysis of the BASIL
trial presented here was, of course, conducted according to a
prespecified statistical plan that was agreed to before the
additional follow-up data became available.
When comparing open surgery with minimally invasive
(endovascular) alternatives, trialists often try to weigh the
relative merits of reductions in short-term mortality and
morbidity against a possible lack of effectiveness, especially
in the longer term (lack of durability). The clinical dilemma
about whether to subject a usually elderly and unfit patient
with SLI to a lesser, arguably safer treatment now—such as
BAP—at the risk of possibly compromising long-term out-
comes of amputation and death can be difficult to analyze
statistically within the confines of a RCT. As discussed
subsequently, the correct interpretation of the data—and
so the appropriate treatment for each individual patient—
will largely depend on the time scale under consideration.
The main findings of the final ITT analysis. A
review of the BASIL trial cohort and the follow-up period
as a whole found no significant difference in AFS and OS
between the two strategies, which some might view as a
negative result and of no great interest. However, such a
perspective overlooks the key purpose of, and outcomes
from, the trial extension and time-dependent survival anal-
ysis prespecified in the statistical plan.
In the short term, BSX is nonsignificantly more hazard-
ous than BAP and is more expensive; so a BAP-first strategy
appears advisable given a 1- to 2-year perspective. In the
longer term, however, BAP is significantly more hazardous
in terms of OS than BSX. For those patients in whom a
longer-term perspective is appropriate, a BSX-first strategy
appears advisable; especially because in the longer term
there is no significant difference in HRQOL or costs be-
tween the two treatments.40
Thus, patients who survived for 2 years and who were
initially randomized to BSX gained a significant 7 months
of additional life expectancy and an additional nonsignifi-
cant 6 months of amputation-free life expectancy over the
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domized to BAP. Although these may not seem large
differences, in the context of a condition with a very poor
overall prognosis that is worse than many common malig-
nancies, affected patients and physicians appear likely to
view them as meaningful gains in life and limb.
A possible explanation for the long-term survival ben-
efit after BSX might have been the survival of the fitter
patients into the second period. However, this explanation
is unlikely because the observed differences in OS in the
period after 2 years were not attenuated by adjustment for
covariates found to be predictive of outcome at baseline.56
Initial perusal of trial data not presented here suggests
that factors that may possibly explain the long-term survival
benefit for BSX include the quality of medical care and
follow-up, enrollment in graft surveillance programs, and a
more complete and durable revascularization as judged by
hemodynamic indices, relief of symptoms, and healing of
minor amputations. At the present time, however, this
remains mere (although we think reasonable) speculation.
The influence of these factors on outcomes is being ana-
lyzed and will be the subject of further separate reports in
due course.
SLI imposes serious health and economic burdens in all
developed countries and in an increasing number of devel-
oping countries. As a result of uncontrolled tobacco con-
sumption and the increasing prevalence of diabetes across
the world, the global burden of SLI is likely to grow
significantly in the future.
As with any common and serious condition, it is imper-
ative that, where possible, management decisions are based
on level I evidence. The BASIL trial suggests that a BSX-
first strategy should normally be regarded as the treatment
of choice for the 75% of SLI patients who are estimated
likely to live 2 years. Those unlikely to survive 2 years
would seem better served by BAP in most cases. A predic-
tive model based on easily obtainable baseline variables that
attempts to estimate the chances of survival of “BASIL-
like” patients to 2 years has been developed and is the
subject of a further separate report.56
Improving the prognosis for severe limb ischemia.
One possible, although somewhat “glass half empty” con-
clusion that might be drawn from the BASIL trial, and
other multicenter or population-based reports that reflect
SLI outcomes across a whole health economy, is that the
prognosis for SLI patients is bleak, almost regardless of
what treatment is offered. From this perspective, we com-
ment below on the trial outcomes and discuss what might
be done differently going forward to try to improve this
overall outlook.
Medical therapy. The BASIL trial has been criticized
for reporting low levels of best medical therapy (BMT),
such as antiplatelet agents and lipid-lowering therapy, at
the time of randomization. There is no doubt that levels of
BMT were disappointingly low and it would be comforting
to think that it was a historical problem, now resolved, that
simply reflected the timing of recruitment period 1999 to
2004. However, currently available data clearly show that isnot the case; nor is it a phenomenon restricted to the UK
health care system. Thus, more recent data from the UK57
andNorth America show that there is still very considerable
room for improvement when it comes to implementing
evidence-based BMT58,59 and, in particular, lipid-lowering
treatment58,60-62 in patients with PAD generally and those
(highest risk) patients with SLI/CLI specifically. Such
treatment will almost certainly increase overall survival and
improve the results of surgical and endovascular interven-
tions63-65 at relatively little additional cost. This must
surely be a highest priority for the global vascular commu-
nity.
Outcomes of BSX. If physicians are going to be per-
suaded to take note of the BASIL trial data and recommen-
dations in everyday clinical decision making, they will need
to be persuaded that the results of BASIL reflects the
current standard of care.66 The problem is that the BASIL
trial data set is not easily comparable against other data
available in the literature because multicenter data are
limited, no other RCTs are available for meta-analysis, and
because of the particular characteristics of the patients
eligible for and so admitted to the BASIL trial.
Currently, the largest and best data set of vein BSX for
CLI comes from the Edifoligide for the Prevention of
Infrainguinal Vein Graft Failure (PREVENT) III trial of a
novel drug (edifoligide) hypothesized to reduce vein graft
failure. Although the drug was not shown to be effective,
the trial provided prospectively gathered, high-quality data
on 1404 BSX procedures undertaken in80 North Amer-
ican centers between 2001 and 2003. However, unlike
BASIL, only excised vein grafts were undertaken (no pros-
thetic or in situ grafts were included), and the follow-up
was short at only 12 months.15 Furthermore, because of
the hypothesis being tested,67 the trial protocol mandated
an especially intensive graft surveillance and reintervention
program.
Nevertheless, reported short-term outcomes to 12
months for comparable PREVENT III and BASIL trial
patients were similar.15 AFS and OS rates in BASIL are
also similar to those reported by others around the same
period.68,69 So it would seem that the BSX outcomes
reported in BASIL are representative of what can reason-
ably be achieved in this type of patient across the health
economies of most developed countries. However, we ac-
cept that physicians in certain centers of excellence may
believe that their own results are substantially better than
those usually reported from multicenter and registry
studies.
The BASIL trial has been criticized for not specifying a
standard follow-up protocol, which it has been suggested
should have included (at least for the bypass grafts)mandatory
duplex ultrasound-based graft surveillance and reintervention
when certain hemodynamic criteria were met.70,71 We have
discussed this issue elsewhere37 and point out that such an
approach was not regarded as standard of care in the UK at
the time the trial was designed. In fact, even today, al-
though some form of graft surveillance seems intuitively
beneficial, the only RCT to examine this controversial area
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duplex-based surveillance.64,72
Angioplasty outcomes. The BASIL trial has been
criticized for the very low use of stents (9 cases). We have
discussed this issue elsewhere.37 Stenting of infrainguinal
arteries was not regarded as standard of care in the UK at
the time the trial. Even today, the evidence that stenting
improves clinical outcomes compared with what can be
achieved by angioplasty alone remains limited, especially in
patients with SLI/CLI as opposed to intermittent claudi-
cation.73
The high failure rate and reintervention rate reported
after BAP in BASIL has also been criticized.37 However,
our data are similar to that presented by others in patients
with extensive multilevel disease.6,24,27,39,74 It is a rapidly
developing field, and new pharmacologic30,75,76 and pro-
cedural and device developments are likely to improve the
results of endovascular therapies for lower limb ischemia of
all severities in the future.1,74,77-82
Choice of trial end points. The primary aim of the
BASIL trial was to determine whether a BSX-first or a
BAP-first revascularization strategy was associated with a
better clinical outcome for patients. However, defining
better is not always straightforward, and end point choices
made by investigators clearly affect trial design, analysis,
and interpretation in a number of important respects. After
much discussion, for the purposes of BASIL, we chose to
define better as improved AFS and used this as the primary
end point for the power calculation and the prespecified
statistical plan when we finalized the design of the trial in
1998. We did so mainly because we believe AFS is the most
clearly understandable and unambiguous measure of the
primary purpose of revascularization; namely, to preserve
limb and, so, life. We understand that AFS remains the end
point required by the United States Food and Drug Ad-
ministration for such studies.
During the last 10 years, our understanding of how the
choice of single and composite clinical, and increasingly,
surrogate end points can influence trial outcomes, interpre-
tation, and thus design has become increasingly sophisti-
cated. The thoughtful and transparent use of such end
points can undoubtedly increase knowledge and under-
standing83; however, they can lead to a lack of clarity, an
inability to compare different studies,84 and even to concerns
around the appropriateness of regulatory approval.85-87
The BASIL trial has been criticized for not using “pa-
tency” as the primary outcome.We have discussed this issue
at length elsewhere.37 In short, we wished specifically to
compare two strategies not just two “one-off” procedures.
As such, we thought powering or interpreting the trial in
the context of measures of hemodynamic success (patency,
ankle pressure) or other end points as surrogates for mean-
ingful clinical outcomes would have been inappropri-
ate.20,88 Pragmatically, assessing patency after BAP in a
uniform manner across 27 centers would have been logis-
tically very difficult.
Choice of entry criteria. It has been suggested that
the BASIL trial cannot be usefully generalized to the ma-jority of patients with CLI. As very clearly stated through-
out the article, even in the very title of the trial itself, this
was emphatically not a trial of patients with “critical limb
ischemia” as defined by the European Consensus Docu-
ment, which was the competent document in the UK at the
time the trial protocol was finalized in 1998.36 Rather, the
patients admitted to BASIL had “severe limb ischemia,”
which is the same as the European Consensus Document
definition of CLI but, crucially, without the requirement to
have an ankle pressure 50 mm Hg. This is perhaps a
subtle but, nevertheless, a very important distinction that
needs to be fully grasped in order to understand the aims,
rationale, and potential value of the BASIL trial in the
context of everyday practice and the rest of the literature.
After much consideration, trial investigators and partic-
ipants decided to admit SLI patients, and not just CLI,
patients to the BASIL trial for a number of reasons:
First, 50 mmHg is arguably an arbitrary cutoff. Does a
patient who requires opiate analgesia for rest pain and with
a gangrenous toe not have limb-threatening ischemia and
not require immediate or early revascularization just be-
cause the ankle pressure is 60 mm Hg?
Second, measurement of ankle pressure and pressure
indices in these patients is subject to interobserver and in-
traobserver variation.89 Does a patient have limb-threatening
ischemia that requires immediate or early revascularization
on a day when the ankle pressure is measured at 45 mmHg
but not on another day when it is 55 mm Hg?
Third, when compared with BSX, BAP might have the
most to offer to those at the better end of the spectrum of
patients with rest pain and tissue loss. Many of these pa-
tients will require immediate or early revascularization to
relieve severe pain or heal tissue loss, or both, but their
ankle pressure will be50 mmHg. Would excluding such
patients on the basis of an arbitrary hemodynamic cutoff
from a trial where one of the arms was angioplasty make any
sense?
Fourth, it became clear from our Delphi consensus
studies that only a small proportion of patients with true
“CLI” were deemed by vascular surgeons and intervention-
alists at that time to have a pattern of disease that they
believed was equally suitable for BAP and BSX (gray area of
clinical equipoise).33,34
Furthermore, at the time the BASIL trial was designed,
Wolfe and Wyatt90 from the UK had recently written an
influential report describing what they termed “subcritical
limb ischemia” (SCLI), which they defined as rest pain and
ankle pressure 40 mm Hg, and they redefined CLI as
tissue loss or ankle pressure 40 mm Hg, or both. These
authors recommended on the basis of an analysis of 20
publications containing6000 patients that future studies
should stratify by SCLI/CLI because the two groups had
very different patterns of disease, responses to treatment,
and outcomes. More recently, other respected authorities
have also recognized a similar group of patients who occupy
a poorly defined hemodynamic area between disabling
claudication and true CLI.91
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chose to use the term “severe limb ischemia” (SLI) to cover
SCLI and CLI and to admit all such patients to the trial.
However, in line with the recommendations of Wolfe and
Wyatt, we stratified the randomization according to
whether the patient had rest pain only or tissue loss also and
by whether their ankle pressure was50mmHg.We chose
50 mm Hg rather than 40 mm Hg to comply with ECD
CLI guidelines.
In fact, 336 of 452 (74.3%) of the BASIL patients had
tissue loss, which is very similar to that reported in many
other studies of intervention for SLI/CLI. Only 93 pa-
tients had rest pain without tissue loss and an ankle pressure
50 mmHg, and 137 had an ankle pressure50 mmHg.
As expected from the randomization process, these propor-
tions were the same in both trial arms.
So, although it is quite true that the BASIL trial de-
scribes a group of patients who had, overall, less severe
disease than studies where the 50mmHg is strictly adhered
to, we think:
1. the admission criteria were clear;
2. the admission criteria were appropriate given the aims of the
trial;
3. all the patients randomized were thought at the time of ran-
domization to require early or immediate revascularization to
relieve pain or heal tissue loss, or both, and were quite clearly
not, as has been suggested, only claudicant patients (this is
discussed further below); and
4. because BASIL reported transparently in detail the clinical and
anatomic (angiographic)39 characteristics of the randomized
patients, physicians will be able to make an informed judgment
about the extent to which their patients are similar to or
different from those described here (this is discussed further
below).
It has been suggested that many of the patients did not
actually have true limb-threatening ischemia because not all
patients went forward to immediate revascularization.37
The number of patients who did not receive timely inter-
vention was, in reality, small. In some cases, this was be-
cause the patient’s condition deteriorated and the patient
became unfit, especially for BSX; such patients fared badly.
In other patients the ischemic pain or tissue loss improved
with best medical and nursing care so that immediate
revascularization was not required or was refused by the
patient. As reported by Wolfe and Wyatt, some of these
patients did quite well in the longer term without interven-
tion. Even some patients with “true” CLI deemed unsuit-
able for revascularization have been reported to have quite
low rates of short-term (6- and 12-month) limb loss and
death with best medical and nursing care.92 We believe the
BASIL data reflect the clinical realities of looking after this
group of patients and demonstrate the value of developing
predictive tools that can help physicians match the available
treatments to individual patient’s needs and circumstances.56
Patient selection and trial generalizability. At the
same time, the BASIL trial has been criticized by some for
studying a group of “highly selected” patients that does notreflect the generality of patients affected by CLI (this has
been discussed above) and by others for allowing a too
heterogeneous a group of patients to be randomized (not
selective enough). We were well aware that in common
with every other RCT, there was going to be a trade-off
when the BASIL trial was designed between purity of
sampling and generalizability that could never be fully
resolved to everyone’s satisfaction.
The BASIL trial audit35 found that 50% of patients
presenting to six major UK vascular units with SLI due to
infrainguinal disease were not considered suitable for, or to
require, or to agree to immediate or early revascularization.
Some have expressed surprise at this statistic and suggested
that it may be something unique to the UK health service.
However, perusal of the literature reveals that few, if any,
contemporary studies explicitly present data that allow the
“community” revascularization rate in other countries to
be determined.15,93 The BASIL trial has been almost
uniquely transparent in placing the revascularized patients
with the total population of consecutive patients presenting
with SLI to the major participating centers. Until data to
the contrary are reported, we think the BASIL audit data
are likely to reflect data found in many other health care
economies, especially where, unlike in the UK, access to
care is dependent upon an ability to pay.
With regard to selection, during the 6-month BASIL
audit, of the 236 patients presenting with SLI due to
infrainguinal disease and who were considered to require
and to be fit for immediate or early revascularization, 70
(29%) were regarded as suitable for randomization into
BASIL. Of these, 22 (31%) refused trial entry and 48 (69%)
were randomized.
It has been suggested that this is a highly selected
cohort and that the BASIL trial data therefore have little
relevance to the overall treatment of CLI. We have dis-
cussed this above, but so crucial is this issue to a proper
understanding of the purpose, rationale, scope, and value
of the BASIL trial that the arguments bear further elabora-
tion.
The aim of pragmatic RCTs like BASIL is to collect a
heterogeneous group of patients requiring treatment (in
this case for SLI) from a heterogeneous group of surgeons
and interventionalists working according to their preferred
methods in a large number of centers but then, crucially, to
apply the rigor of randomization to the treatment received.
It is the polar opposite of the single-surgeon, single-center
experiences of treating a more homogenous group of pa-
tients in a highly standardized manner. The huge benefit of
the former over the latter is that it provides a wholly
unbiased report of what can be realistically achieved in the
aggregate across a health economy through the application
of two different therapeutic strategies where there is a
genuine “gray area of clinical equipoise.”
In this respect the BASIL trial is no different from,
for example, the carotid and aortic aneurysm trials that
now guide intervention in those areas. Specifically, the
BASIL trial compared (for the first and only time in a
randomized manner) a BSX-first strategy with a BAP-
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immediate or early revascularization for SLI due to in-
frainguinal disease and who, in the opinion the respon-
sible surgeon and interventionalist, could be equally well
treated by either BSX or BAP (the gray area of equi-
poise). So, of course, to be eligible for admission to the
trial the patient had to have:
1. SLI due to infrainguinal disease;
2. require and be fit for immediate or early revascularization by
either means; and
3. have a clinical and anatomic (angiographic) pattern of disease
that led both the surgeon and the interventionalist to believe
there was a grey area of equipoise.
As discussed above, about 30% of SLI patients were
thought to meet these criteria and be eligible for the trial.
The other 70% were considered (rightly or wrongly) to be
better treated by BSX, by BAP, with best medical and
nursing care only, or by primary amputation. Such patients
could not therefore be randomized by those physicians.
The only other “selection” was that the patients had to be
able and willing to give fully informed written consent.
Given the nature of the patients and the two treatments on
offer, a remarkably high proportion (about 70%) of eligible
patients agreed to be randomized; this is a great credit to
the vascular teams in the 27 centers.
If readers choose to interpret this as “selection” in the
pejorative sense of the term, then so be it. However, in
keeping with all other RCTs, we could only randomize
patients who were suitable for both treatment strategies
and in whom there was genuine doubt about which strat-
egy would best serve their interests. To do otherwise
would, of course, have been highly inappropriate both
scientifically and ethically. All RCTs, including BASIL,
work on the basis of the “gray area of clinical equipoise”
(uncertainty principle), which will of course (we know this
from our Delphi consensus studies) vary between individ-
ual surgeons and interventionalists working in different
units. Such judgements also change over time, and it would
be interesting to repeat the Delphi consensus studies that
preceded the BASIL trial in the light of the BASIL trial
data.33,34
Power of the trial. The power of the BASIL trial has
been described as “marginal,” with which we would dis-
agree. The sample size calculations proposed that 223
patients per treatment would be needed for a 90% power to
detect a 15% difference in 3-year AFS at the 5% significance
level. This calculation was based on the assumption that the
3-year survival value might be 50% in one group and 65% in
the other.35 In fact, these overall estimates turned out not
to be unreasonable, and 452 patients were randomized; of
whom only 4 were lost to follow-up.
The other important point is that the real power of a
trial depends more on the number of end points than on
the number of patients randomized; and BASIL patients
provided no shortage of end points (amputations, deaths).
But, of course, if one chooses to embark on subgroup
analysis, then the power weakens; we have been careful notto do this. We have also been careful not to over-interpret
the longer-term follow-up data; hence, the decision to
extend follow-up after reporting (what turned out to be
interim) results in the Lancet in 2005.
Prosthetic grafts. Some have argued that it would
have been better if the trial had excluded patients requiring
prosthetic grafts. This is an issue that the trial investigators
and participants considered carefully when designing the
trial in the late 1990s.37 At that time, however, it was
common practice to use prosthetic grafts, usually with
some form of venous cuff or collar, in SLI patients. Such
surgery is still undertaken in the UK and elsewhere, al-
though one suspects in smaller numbers than a decade ago.
Excluding prosthetic grafts would probably have improved
the results of surgery but may have led to accusations of
cherry picking and bias from the interventional community.
It seems likely to us that the interventional community
would have “retaliated” by requesting that certain high-risk
angioplasty cases be removed from the analysis. Instead, we
have conducted a large pragmatic multicenter RCT where
all angioplasty and all surgical outcomes have been ana-
lyzed by ITT.
By including prosthetic grafts and by also offering a
“by-treatment-received” analysis in a separate article,37 we
have also been able to draw (with appropriate caveats) some
conclusions about the relative merits of vein vs prosthetic
bypass compared with angioplasty. However, we must be
very careful not to over-interpret nonrandomized data.
CONCLUSIONS
Much of the available literature gives the impression
that every patient who presents with SLI/CLI can and
should undergo revascularization and that the results of
those revascularizations are largely good. In reality, how-
ever, a significant proportion of such patients, even those
with the most severe “unreconstructable” disease, can be
managed quite successfully, at least in the short-term, with
best medical treatment and nursing care.92,94 Furthermore,
attempts at revascularization often fail, and many SLI/CLI
patients with a very limited life expectancy andHRQOL are
not well served by, often repeated, attempts at limb sal-
vage.95-98
Although AFS is an appropriate and unambiguous pri-
mary trial end point, it does not give much information
about the quality of revascularization. It is quite possible for
a patient to enjoy a reasonable HRQOL with a primary
amputation, especially if the patient’s premorbid mobility
status was already limited, and for another patient to have a
very poor QOL due to chronic pain and wound problems,
despite an apparently successful revascularization.88,97-99
The often-assumed inverse relationship between revascu-
larization and amputation rates has not been borne out in
an analysis of recent UK data.100
It is very important, therefore, that vascular surgeons
and interventionalists do not become excessively lesion-
centric and undertake increasingly heroic attempts at limb
salvage while losing focus on the individual patient’s needs
and expectations.1,43,88,90,91,95-98,101 To try to assess these
JOURNAL OF VASCULAR SURGERY
May Supplement 201014S Bradbury et alissues, we have collected data on HRQOL, preintervention
and postintervention ankle pressure, pain, ulcer healing,
and the incidence and outcome of minor amputations.
These data are being analyzed and will be the subject of
further separate reports in due course.
Going forward, the BASIL investigators have also
joined with others under the auspices of the Society for
Vascular Surgery (SVS) to establish a working group to
examine the data that might support objective performance
goals (OPG) for current and future CLI therapies. In so
doing, the group recognizes that large sample sizes are
required to examine safety and efficacy, especially within
critical subgroups. Data contributed fromBASIL and other
prospective multicenter studies are currently being used
towards these ends.102,103
Summary of BASIL trial recommendations. The
BASIL trial suggests that those SLI patients who are likely
to live 2 years are probably better served by a BSX-first
strategy, preferably with vein.37 Those SLI patients who are
unlikely to live 2 years, and possibly those in whom vein is
not available for bypass, are probably better served by a
BAP-first strategy because they are unlikely to survive to
reap the longer-term benefits of surgery, they may be more
likely to suffer surgical morbidity and mortality, and be-
cause angioplasty is significantly less expensive than surgery
in the short-term.
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